載入中
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
前收盤價
US$4.81
−US$0.04 · -0.82%
盤中時間採用ET。市場資料可能有所延遲。
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
日內區間
目前US$4.81
52週區間
目前US$4.81
盤中時間採用ET。市場資料可能有所延遲。
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
日內區間
目前US$4.81
52週區間
目前US$4.81
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.34億 USD | 1.4億 USD | 8907.7萬 USD | 4900.5萬 USD | 2259.3萬 USD |
| 銷貨成本 | 3146.9萬 USD | 4098.4萬 USD | 3531.2萬 USD | 2767.7萬 USD | 1807.6萬 USD |
| 毛利 | 1.03億 USD | 9894.3萬 USD | 5376.5萬 USD | 2132.8萬 USD | 451.7萬 USD |
| 研究與開發 | 3854.9萬 USD | 3436.7萬 USD | 2905.1萬 USD | 2598.1萬 USD | 2449.9萬 USD |
| 銷售、一般及管理費用 | 1.13億 USD | 1.01億 USD | 7479.9萬 USD | 5866.5萬 USD | 3280.5萬 USD |
| 營業費用 | 1.51億 USD | 1.36億 USD | 1.04億 USD | 8464.6萬 USD | 5730.4萬 USD |
| 利息收入 | 250.8萬 USD | 947.4萬 USD | 657.4萬 USD | 151.7萬 USD | 5.4萬 USD |
| 利息支出 | 4萬 USD | 2.1萬 USD | 330.8萬 USD | 494.6萬 USD | 368.2萬 USD |
| 折舊和攤銷 | 326.6萬 USD | 362.4萬 USD | 424.3萬 USD | 402.2萬 USD | 398.8萬 USD |
| 營業利益 | −4819萬 USD | −3685.8萬 USD | −5008.5萬 USD | −6331.8萬 USD | −5278.7萬 USD |
| 淨利 | −3894.3萬 USD | −2745.5萬 USD | −4860.8萬 USD | −6675.6萬 USD | −4868.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.31
上漲空間 51.98%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI899.5萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM509.69萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF300.01萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO168.24萬0.01%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA96.71萬0.00%218.24億 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT87.57萬0.00%220億 USD0.09%US$319.01+1.64%
iShares Micro-Cap ETFIWC60.61萬0.05%13.17億 USD0.60%US$183+0.11%
Invesco RAFI US 1500 Small-Mid ETFPRFZ31.01萬0.01%26.7億 USD0.36%US$53.16+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
